Docetaxel
- Generic Name
- Docetaxel
- Brand Names
- Taxotere, Docetaxel Accord, Docetaxel Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C43H53NO14
- CAS Number
- 114977-28-5
- Unique Ingredient Identifier
- 699121PHCA
- Background
Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiometric ratio, allowing it to prevent cell division and promote to cell death. Compared to paclitaxel, docetaxel is two times more potent as an inhibitor of microtubule depolymerization. Docetaxel binds to microtubules but does not interact with dimeric tubulin.
The use of docetaxel may lead to udesired outcomes such as hepatic impairment, hematologic effects, enterocolitis and neutropenic colitis, hypersensitivity reactions, fluid retention, second primary malignancies, embryo-fetal toxicity, and tumor lysis syndrome. Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.
- Indication
Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC. For the treatment of metastatic castration-resistant prostate cancer, docetaxel is indicated with prednisone. Docetaxel is also indicated with cisplatin and fluorouracil for untreated, advanced gastric adenocarcinoma, including the gastroesophageal junction, and with cisplatin and fluorouracil for induction treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN).
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
- Associated Therapies
- -
Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
- Conditions
- First Posted Date
- 2004-03-15
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Montefiore Medical Center
- Registration Number
- NCT00004864
- Locations
- 🇺🇸
Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States
Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function
- First Posted Date
- 2004-03-12
- Last Posted Date
- 2010-01-13
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT00002901
- Locations
- 🇺🇸
Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸University of California Davis Cancer Center, Sacramento, California, United States
Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00079170
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Japan Multinational Trial Organization
- Registration Number
- NCT00079287
- Locations
- 🇯🇵
Nagoya University Hospital, Aichi, Japan
🇯🇵Asahikawa Medical College, Asahikawa, Japan
🇯🇵National Hospital Organization - Ehime National Hospital, Ehime, Japan
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 70
- Registration Number
- NCT00079118
- Locations
- 🇺🇸
Kenton Oncology, Incorporated, Kenton, Ohio, United States
🇺🇸McDonough District Hospital, Macomb, Illinois, United States
🇺🇸Hurley Medical Center, Flint, Michigan, United States
Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer
- First Posted Date
- 2004-03-04
- Last Posted Date
- 2017-07-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 19
- Registration Number
- NCT00005096
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer
- Conditions
- First Posted Date
- 2004-03-03
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00004175
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States
🇺🇸Monroe Medical Associates, Chicago, Illinois, United States
Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach
- Conditions
- Interventions
- First Posted Date
- 2004-03-03
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 47
- Registration Number
- NCT00004235
- Locations
- 🇺🇸
CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States
🇺🇸Medcenter One Health System, Bismarck, North Dakota, United States
🇺🇸CCOP - Geisinger Clinic and Medical Center, Danville, Pennsylvania, United States
Docetaxel in Treating Children With Recurrent Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2004-03-01
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00002825
- Locations
- 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer
- Conditions
- First Posted Date
- 2004-02-25
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00004223
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸Veterans Affairs Medical Center - Palo Alto, Palo Alto, California, United States
🇺🇸Veterans Affairs Medical Center - Lakeside Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.